MLYS.O

MLYS09 Dec 2024
Healthcare
$13.51
+0.04 (+3.56%)
Lowest Today
$13.39
Highest Today
$13.79
Today’s Open
$13.51
Prev. Close
$13.21
52 Week High
$16.91
52 Week Low
$6.83
To Invest in MLYS.O

MLYS.O

Healthcare
MLYS09 Dec 2024
+0.04 (+3.56%)
1M
3M
6M
1Y
5Y
Low
$13.38
Day’s Range
High
$13.78
13.38
52 Week Low
$6.83
52-Week Range
52 Week High
$16.9
6.83
1 Day
-
1 Week
-2.88%
1 month return
-6.21%
3 month return
+10.33%
6 month return
-2.74%
1 Year return
+82.36%
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
657.44 mln
PB Ratio
2.77
PE Ratio
0
Enterprise Value
660.54 mln
Total Assets
251.64 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Organisation
MLYS.O
Employees
28
Industry
Biotechnology
CEO
Mr. Jon  Congleton
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step